Clinical trial NCT05132075 · Non-Small Cell Lung Cancer
Oncology research
28 Sep 2026
NCT05132075 — is «active, not recruiting» on ClinicalTrials.gov.
Clinical trial NCT05132075 (phase III) is «active, not recruiting» on ClinicalTrials.gov.
Condition: Non-Small Cell Lung Cancer · Registered interventions: JDQ443, docetaxel · Recorded dates (source): 2022-06-15, 2026-09-03, 2021-11-24, 2026-09-25.
Study summary (source: ClinicalTrials.gov):
This is a phase III randomized open label study designed to compare JDQ443 as monotherapy to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previously treated with a platinum-based chemotherapy and immune checkpoint inhibitor therapy either in sequence or in combination.